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Allogeneic stem cell transplantation (SCT) is the most effective treatment option for many hematologic
malignancies, but graft-versus-host disease (GVHD) remains a major cause of treatment failure. Along with
well-established risk factors for transplantation outcomes, recent single-center studies have identiﬁed a birth
order effect in HLA-identical sibling SCT, with lower rates of acute and chronic GVHD and improved overall
survival when the donor is younger than the recipient. One hypothesized mechanism for this effect is
microchimerism due to fetomaternal and transmaternal sibling cell trafﬁcking during pregnancy as the donor
is exposed to recipient antigens in utero. The aim of the present study was to validate previously reported
single-center data in a large, multicenter cohort provided by the Center for International Blood and Marrow
Transplantation. All adult and pediatric patients (n ¼ 11,365) with a hematologic malignancy who underwent
allogeneic SCT with a graft from an HLA-identical sibling donor between 1990 and 2007 were included. When
donors were younger than recipients, there was a signiﬁcantly lower rate of acute GVHD grade II-IV and
chronic GVHD in children, as well as a lower rate of chronic GVHD in adolescents. However, the hypothesized
overall positive effect of lower relapse and better survival when donors are younger than recipients was not
observed. Our data suggest that if otherwise equally matched, a graft from a younger sibling may be superior
to a graft from an older sibling for children and adolescents undergoing SCT.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION outcome, an impact of birth order in HLA-identical sibling
Allogeneic stem cell transplantation (SCT) is a curative
treatment option for many hematologic malignancies. How-
ever, relapse and graft-versus-host-disease (GVHD) remain
themost important causes of treatment failure [1]. Given that
HLA disparity between donor and recipient is the most crit-
ical factor governing the incidence and severity of GVHD,
the donor search focuses on HLA-identical siblings ﬁrst [2].
Along with well-established risk factors for transplantationongress of the European Hematology
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13.01.020transplantation has been described in recent retrospective
analyses [3,4].
Themechanism behind this birth order effect may include
microchimerism by fetomaternal cell trafﬁcking during
pregnancy, leading to exposure to nonself antigens in both
mother and child [5-7]. This early perinatal exposure and
resultant microchimerism in the mother or siblings may
result in B cell and T cell sensitization and the induction of
T regulatory cells, which could affect the activation of donor
lymphocytes in response to later antigen (re)exposure after
SCT [8,9]. In the context of pregnancy and SCT immunology,
an increased risk of GVHD after transplantation from parous
female donors compared with nulliparous donors has been
observed in HLA-identical SCT [10-14]. In the haploidentical
setting, maternal grafts are superior in terms of disease-free
survival (DFS), relapse incidence, and mortality, perhapsTransplantation.
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children [15,16]. To further evaluate the impact of recipient
and donor birth order on the outcome of sibling SCT,
we performed a retrospective analysis using the database
of the Center for International Blood and Marrow Trans-
plantation (CIBMTR).PATIENTS AND METHODS
The aim of this study was to validate previously reported single-center
data in a multicenter cohort provided by the CIBMTR. This multicenter
analysis included patients who underwent an HLA-identical sibling SCT
recorded in the CIBMTR database between 1990 and 2007. Only HLA-
identical sibling transplantations were included, because birth order
effects would not be expected with unrelated donors.
Adult and pediatric patients with a diagnosis of acute leukemia, mye-
lodysplastic syndrome, or chronic myelogenous leukemia undergoing a ﬁrst
allogeneic SCT were included. Patients with nonmalignant disorders were
excluded, given our interest in examining effects on relapse. Cord blood
recipients, recipients age <2 years (because there were only a few patients
in this cohort), and donorerecipient pairs in which the age difference was
reported as >15 years apart or <1 year apart were excluded, to improve the
homogeneity of the cohort. Disease stage was categorized according to
CIBMTR conventions as early (acute leukemia in ﬁrst complete remission,
refractory anemia, refractory anemia with ringed sideroblasts, or chronic
myelogenous leukemia in ﬁrst chronic phase) or late (relapsed or refractory
disease). All other disease types and stages were classiﬁed as intermediate.
Patients were assigned to 1 of 2 groups: recipient older than donor (R>D)
or donor older than recipient (D>R).
Outcomes were analyzed in terms of OS, relapse rate and mortality, DFS,
treatment-related mortality, acute GVHD (aGVHD), and chronic GVHD
(cGVHD).
Statistical analyses were performed with SAS 9.2 (SAS Institute, Cary, NC),
comparing differences between the R>D and D>R groups using the c2 test,
t-test, or nonparametric tests as appropriate. Probabilities of OS andDFSwere
calculated using Kaplan-Meier estimates. The log-rank test was used for
univariate comparisons. Risk factors for outcomes were evaluated in multi-
variate analyses, using Cox proportional hazard models. All models includedTable 1
Recipient and Donor Characteristics
Variable R>D Group
Number of patients 5870
Age at SCT, yr, median (range) 35 (2-75)
Age at SCT, yr, n (%)
Children (0-9) 319 (5)
Adolescents (10-19) 814 (14)
Adults (20þ) 4737 (81)
Male sex, n (%) 3296 (56)
KPS 90 pre-SCT, n (%) 4546 (77)
Disease at SCT, n (%)
Acute myelogenous leukemia 2234 (38)
Acute lymphoblastic leukemia 1244 (21)
Chronic myelogenous leukemia 1898 (32)
Myelodysplastic syndrome 494 (8)
Stem cell source, n (%)
Bone marrow 4244 (72)
Peripheral blood stem cells 1626 (28)
Conditioning regimen, n (%)
Myeloablative 5440 (93)
Reduced-intensity/nonmyeloablative 430 (7)
GVHD prophylaxis, n (%)
Calcineurin inhibitor þ MTX, other 4420 (75)
Calcineurin inhibitor other (no MTX) 1125 (19)
T cell depletion 325 (6)
Donor-recipient sex match, n (%)
Female-male 1490 (25)
All other 4380 (75)
Donor age, yr, median (range) 30 (<1-69
Year of SCT, n (%)
1990-1994 2504 (43)
1995-1999 1756 (30)
2000-2004 1086 (19)
2005-2009 524 (9)
Survivor follow-up, mo, median (range) 80 (1-233)
KPS indicates Karnofsky Performance Score; MTX, methotrexate.the main effect of interest (R>D versus D>R), as well as other covariates with
a statistical signiﬁcance level of P < .05. Potential covariates included
donorerecipient sex match, cytomegalovirus (CMV) status, race, pre-
transplantation performance status, disease and stage, time from diagnosis to
transplantation, conditioning intensity, graft type, GVHD prophylaxis,
antithymocyte globulin (ATG), and year of SCT. Recipient age and donor age
were tested in separate models because of their correlation with birth order.RESULTS
This retrospective analysis included a total of 11,365
patients who underwent allogeneic SCT from HLA-identical
sibling donor (5870 in the R>D group and 5,495 in the
D>R group). Patient characteristics are summarized in
Table 1. The median age of patients at SCT was 35 years
(range, 2 to 75 years) in the R>D group, compared with
31 years (range, 2 to 72 years in the D>R group (P < .0001).
Acute myelogenous leukemia was the most common indi-
cation for SCT (38% in both groups). Bone marrow was the
predominant stem cell source (72% in the R>D group and
73% in the D>R group). Most patients had early-stage disease
at the time of SCT (80% in the R>D group and 81% in the D>R
group; P ¼ .14). The conditioning regimenwas myeloablative
in more than 90% of the recipients in each group. In both
groups, most patients received a calcineurin inhibitor-based
GVHD prophylaxis regimen. Few patients had ATG exposure
(4% in the R>D group and 3% in the D>R group); these
patients were excluded from analysis. Because exposure
to CMV increases with age, the D>R group was more likely
than the R>D group to be donor CMV-positive/recipient
CMV-negative (14% versus 8%) and less likely to be donor
CMV-negative/recipient CMV-positive (12% versus 20%).
Once it was determined that patient age interacted with
birth order, patient age was divided into 3 groups, to reduceD>R Group P Value
5495
31 (2-72) <.0001
<.0001
542 (10)
911 (17)
4042 (74)
3248 (59) .001
4237 (77) .67
<.0001
2091 (38)
1399 (25)
1608 (29)
397 (7)
.27
4024 (73)
1471 (27)
5152 (94) .02
343 (6)
.67
4167 (76)
1043 (19)
285 (5)
.21
1452 (26)
4043 (74)
) 37 (3-79) <.0001
.16
2426 (44)
1639 (30)
933 (17)
497 (9)
83 (0.6-228) .49
Figure 2. Lower incidence of cGVHD in children (age 2-9 years) in the R>D
group.
Table 2
Multivariate Analysis
RR (95% CI) for R>D* P Value
OS
Children 0.85 (0.68-1.06) .15
Adolescents 1.04 (0.90-1.21) .58
Adults 1.06 (0.98-1.14) .14
DFS
Children 0.83 (0.67-1.04) .10
Adolescents 1.03 (0.90-1.20) .65
Adults 1.03 (0.96-1.10) .48
NRM
Children 0.90 (0.61-1.31) .58
Adolescents 1.11 (0.90-1.37) .34
Adults 1.03 (0.95-1.12) .48
Relapse
Children 0.85 (0.65-1.11) .23
Adolescents 1.02 (0.83-1.24) .87
Adults 1.04 (0.92-1.17) .58
aGVHD grade II-IV
Children 0.68 (0.54-0.87) .002
Adolescents 0.94 (0.81-1.11) .50
Adults 0.97 (0.89-1.05) .38
aGVHD grade III-IV
Children 0.89 (0.60-1.32) .56
Adolescents 0.86 (0.66-1.12) .25
Adults 0.96 (0.85-1.08) .46
cGVHD
Children 0.51 (0.34-0.76) .001
Adolescents 0.68 (0.56-0.83) .0001
Adults 0.99 (0.91-1.08) .83
See text for a list of signiﬁcant clinical covariates. Stratiﬁed for signiﬁcant
nonproportional covariates.
* D>R, RR ¼ 1.0.
C. Dobbelstein et al. / Biol Blood Marrow Transplant 19 (2013) 741e745 743model complexity: children (2-9 years; 8%), adolescents
(10-19 years; 15%), and adults (20 years; 77%) (Table 2).
Children age <2 years were excluded, because no recipients
older than donors were identiﬁed in this subgroup.
In children, the R>D group had a lower incidence of
both aGVHD grade II-IV (relative risk [RR], 0.68; 95% conﬁ-
dence interval [CI], 0.53-0.86; P ¼ .0015, adjusted for GVHD
prophylaxis) (Figure 1) and cGVHD (RR, 0.49; 95% CI, 0.33-
0.73; P ¼ .0005, adjusted for graft type and performance
score) (Figure 2). No other clinical covariate was statistically
associated with GVHD. When the analysis was limited to
extensive cGVHD (excluding limited presentation), the inci-
dence remained lower in the R>D group (RR, 0.51; P ¼ .02).
The distribution of organ involvement in the childrenwas 26%
skin, 12% liver, and 13% gastrointestinal in the R>D group and
36% skin,14% liver, and 20% gastrointestinal in the D>R group.Figure 1. Lower incidence of aGVHD grade II-IV in children (age 2-9 years) in
the R>D group.In adolescents, the R>D group had a lower incidence of
cGVHD (RR, 0.67; 95% CI, 0.56-0.81; P  .0001, adjusted for
GVHD prophylaxis, graft type, race, sex match, and year of
SCT) (Figure 3). Results were similar when the analysis was
limited to extensive cGVHD. Birth order was not predictive of
aGVHD or cGVHD in adults.
Given concerns that either recipient or donor age [17]
rather than birth order accounted for the foregoing ﬁnd-
ings, separate models were created to test whether recipient
or donor age per se was associated with aGVHD or cGVHD
in the child and adolescent groups. Neither recipient age nor
donor age was found to predict GVHD in multivariate
models, and the age difference between recipient and donor
was not predictive of GVHD. Finally, no signiﬁcant differ-
ences in OS, DFS, nonrelapse mortality (NRM), or relapse
were detected between the R>D and the D>R groups in any
age cohort.
In addition, several prespeciﬁed subset analyses were
conducted based on the literature. In patients with an early-
stage myeloid disease receiving a T cellereplete peripheral
blood stem cell graft, no associations between birth order
and OS, DFS, or NRM were seen in either the myeloablative
conditioning group or the nonmyeloablative conditioning
group (data not shown).
DISCUSSION
The aim of this study was to evaluate a possible effect of
donor birth order on the incidence of GVHD, relapse, and OSFigure 3. Lower incidence of cGVHD in adolescents (age 10-19 years) in the
R>D group.
C. Dobbelstein et al. / Biol Blood Marrow Transplant 19 (2013) 741e745744after allogeneic SCT for hematologic malignancies in a very
large patient cohort. We found a birth order effect on GVHD
incidence in HLA-identical sibling SCT that depends on
patient age. Our data indicate a reduced incidence of aGVHD,
consistent with a Swiss single-center analysis of 311 patients
that found less aGVHD regardless of patient age, although
that study also reported an association between OS and
relapse incidence [3]. In contrast to patients with hemato-
logic malignancies, the impact of birth order on OS could not
be reproduced in patients with aplastic anemia [18], but
a graft-versus-leukemia effect is not necessary for successful
allogeneic SCT in patients with this diagnosis.
Fetomaternal and maternofetal cell trafﬁcking and per-
sistence are believed to result in at least transient micro-
chimerismwith either sensitization or tolerance [19-21], and
the donor age dependency of these effects may correspond
to the disappearance of microchimerism and immunmodu-
lation over time. In some individuals, fetomaternal traf-
ﬁcking effects may last until adulthood, with HLA-disparate
maternal cells persisting in immunocompetent offspring
even into adult life [22]. In multiparous female blood donors,
minor histocompatibility antigenespeciﬁc cytotoxic T cells
can be detected in peripheral blood mononuclear cells, pre-
sumably owing to exposure to the minor histocompatibility
antigen during pregnancy, for up to 22 years after delivery
[10]. Maternal cells can cross the placenta to reside in fetal
lymph nodes, with the development of CD4þCD25highFox
P3þ T regulatory cells that suppress fetal antimaternal im-
munity and persist at least until early adulthood [20,21].
Undoubtedly, it would have been very interesting to analyze
the inﬂuence of maternal parity; however, these data are not
available in a large registry study and also might be difﬁcult
to evaluate, given that miscarriage, half-siblings, and abor-
tion might inﬂuence a potential microchimerism effect but
be incompletely recorded in the maternal medical history.
Furthermore, male DNA can be detected in growth
factoremobilized peripheral blood mononuclear cells and
CD34-enriched apheresis products from female donors [23].
Dierselhuis et al. [24] recently reported the presence of
functional H-Yespeciﬁc cytotoxic T cells and male micro-
chimerism in female umbilical cord blood. This ﬁnding can
be interpreted as strongly indicative of the existence of a cell
ﬂow between siblings via the mother [24].
We could not conﬁrm an association between donor birth
order and relapse or survival in sibling transplantation re-
cipients in our cohort, and we found no association between
donor birth order and the incidence of GVHD in the adult
transplantation recipients. Differences between our present
results and results of previous studies could be related to
center-dependent strategies, such as increased use of pe-
ripheral blood stem cells [25] and the use of ATG [3,4] or
different GVHD prophylaxis approaches, which may modu-
late the clinical effects of birth order in HLA-identical sibling
SCT [19-21], although we adjusted for these factors if they
were statistically associated with GVHD. The CIBMTR pop-
ulation is more ethnically diverse than previously studied
single-center populations, which might result in different
prognostic genetic markers associated with microchimerism
(eg, HLA), which could mask any birth order effect. Major
strengths of this study include the large sample size of more
than 10,000 transplantation pairs and the ability to adjust for
other important clinical variables that could potentially
confound the posttransplantation outcomes of interest.
Our results might be of particular interest for the pedi-
atric setting, given that cGVHD is the primary cause of latemorbidity and NRM in long-term SCT survivors [26]. Con-
sidering that it is impossible to perform prospective clinical
trials with sufﬁcient power to deﬁnitely address the impact
of birth order in HLA-identical sibling SCT, our observational
data suggest that an HLA-identical sibling donor younger
than the pediatric or adolescent recipient may be superior
to an older one if equally matched for all other established
parameters relevant to donor choice. The advantage for the
recipient may balance other concerns that usually favor
an older sibling, such as larger size, understanding of the
procedure, and better ability to participate in the assent
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